Apply for a grant
The research the CGD Society (CGDS) funds is at the cutting edge,
often exploring solutions that will take many years to refine and apply
clinically. Research that helps CGD sufferers can benefit millions more
because it is a single-gene deficiency, meaning any breakthroughs in CGD
are more likely to shed light on how other genetic disorders work.
Our research strategy
To date, CGDS has awarded more than 50 grants. Our awards have ranged
from a few hundred pounds to cover travel costs to the support of a
programme grant. We support both basic science and applied medical
research, and strongly encourage collaboration between our researchers.
Over the period 2015 - 2018 we will be making available £50,000/year in grant funds.
You can read our research strategy here.
The Chronic Granulomatous Disorder Society is a member of the
Association of Medical Research Charities (AMRC). All AMRC members
support the AMRC position statement on the use of animals in research.
Facts about our funding process
- Peer review is central to our grant awarding process
- We have no geographical restrictions on where we fund
- All full applications undergo external peer review
- A minimum of 3 external reviewers are used per application
- The mean success rate for full applications received between 2008 to 2011 applications was 23%
- We abide by the AMRC’s principles of peer review.
Key target areas for funding
CGDS funds research into the cause, inheritance, diagnosis,
management and treatment of CGD. It is willing to consider research
applications of high quality that address important scientific, clinical
or social questions relating to CGD. The criteria for funding are
excellent science and relevance to and benefit for CGD.
Priority research and scientific areas
CGDS is committed to providing funding in the following areas:
Gene and cellular therapy for CGD as a treatment and potential cure for CGD
Causes and treatment of inflammation in CGD. Understanding the mechanisms involved and improving treatment methods
Causes and treatment of infection in CGD. The mechanisms involved and improving methods of treatment
Basic research concerning the structure and function of the enzyme
NADPH oxidase and identification of possible target pathways for
The grant application process
There is only one round of grant funding each year and a call for
proposals is made in the journal 'Nature' and through our network of
professional members throughout the world. Anyone interested in
applying for a CGD research grant has to first complete a preliminary application.
This gives details of the proposed work, its relevance to CGD and
approximate costings for the work. These preliminary applications are
reviewed by members of our medical panel and lay reviewers from our
Trustee board who rate the applications according to relevance to the
charity’s research strategy and whether the science is likely to lead to
benefit for the CGD community. At this stage approximately 30-50% of
the applications are rejected. Successful applicants are then asked to
submit a full application.
How we decide on funding
Three external independent experts with related research experience
reviews each application. Independent experts are chosen that have no
affiliation to the grant applications and are asked to declare any
conflict of interest in being a reviewer before receiving an
application. All reviewers are expected to respect the applicants'
confidentiality. The CGDS provides guidance to the referees and supplies them a review form
for this process. Peer reviewers are asked to score the applications on
the basis of quality, relevance, originality, feasibility and value for
The CGDS Medical Advisory Panel consider the external
reviewers' recommendations. The panel advises CGDS on the best quality
research to fund and on setting priorities for future CGD research. We
have in place a code of practice and conflict of interest policy and a register of interests
for our Research Advisory Panel by which all members agree to abide
before joining the panel. Panel members can serve up to a maximum of six
years on the panel.
The AMRC approves all our peer review methods and
in 2011 the CGD Society received a certificate of best practice for its
peer review procedures.
Selecting the most promising projects
It is the nature of research that some avenues yield no useful
results, but the CGDS is very careful where donors’ money is spent.
Every application received is fully peer reviewed by external experts
who pass on their advice to our dedicated Advisory Panel. This Panel
then decides which projects would give the best scientific outcomes for
CGD and the best value for money.
Equally important, we demand absolute clarity regarding how grant
funds were spent, and monitor and evaluate carefully. As part of this
process it is a condition of receiving a CGDS research grant that a research grant award report
is submitted annually and final reports are submitted within three
months from the end of the grant. Reports are assessed by members of the
Research Advisory Panel or may be sent to other specialist advisors.
Comments arising from the assessment will be made available to the grant
CGDS: Our integrity
We are well connected with the biggest names in research in our
field; with key hospitals, research establishments, scientists and
medical professionals. We keep up a dialogue with other top bodies to
maximise impact and avoid duplication of research. We are transparent
and accountable, and are happy to provide details or exactly how
research projects spent the money you gave us.
The purpose of these awards is to provide support for a time-limited
project designed to answer a single question or a small group of related
questions. Such questions must be directed towards furthering our
understanding of CGD and/or developing effective treatments for the
condition that fit within the priority areas.
Important notes for applicants
Before a full application can be considered the applicant(s) and the
institution must sign a form stating that they will accept and adhere to
the CGDS Terms and Conditions
for Awards in the event of an award being made. Otherwise the
application will not be considered. The CGDS will not enter into
negotiation regarding this matter.
Please read our Notes for Applicants and our Terms and Conditions of Grant before applying to the CGDS. Make sure your application is relevant to our research strategy.
Our Research Advisory Panel
Read more about our research advisory panel here
- Professor Len Seymour, Chair of Committee, Professor of Gene Therapies, University of Oxford
- Dr Siobhan Burns, Reader and Consultant in Immunology, University College London, Institute of Immunity and Transplantation
- Dr Tayfun Güngör, Head, Stem Cell Transplantation Department (SCT), University Children`s Hospital, Zurich, Switzerland
- Dr Steven Howe, Senior Research Associate, Molecular Immunology Unit, Institute for Child Health, London
- Professor Tom Rogers, Head of Clinical Microbiology, Trinity College Dublin, St James's Hospital, Dublin
- Professor Dirk Roos, Department of Blood Cell Research, Sanquin Research Centre, Amsterdam
- Professor Adriano Rossi, Chair of Respiratory and Inflammation
Pharmacology at the University of Edinburgh/MRC Centre for Inflammation
- Dr Simon Travis, Clinical Director of Gastroenterology and Endoscopy, John Radcliffe Hospital, Oxford
- Dr Adilia Warris, Institute of Medical Sciences, University of Aberdeen
- Andrew Orchard, CGD Society Trustee